Antiproteinuric effect of cilnidipine in hypertensive japanese treated with renin-angiotensin-system inhibitors-A multicenter, open, randomized trial using 24-hour urine collection

Yoshikazu Miwa, Takuya Tsuchihashi, Yuko Ohta, Mitsuhiro Tominaga, Yuhei Kawano, Toshiyuki Sasaguri, Michio Ueno, Hiroaki Matsuoka

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Sustained proteinuria is an important risk factor for not only renal but also cardiovascular morbidity and mortality. Although inhibitors of the renin-angiotensin system (RAS) have been shown to reduce proteinuria. Monotherapy with those drugs is often insufficient for optimal blood pressure (BP)-lowering and therefore, combined therapy is needed. Recent reports suggested that cilnidipine, a dual L-N-type calcium channel blocker, has renoprotective effect by dilating both efferent and afferent arterioles. In this study, a multicenter, open, randomized trial was designed to compare the antiproteinuric effect between cilnidipine and amlodipine when coupled with RAS inhibitors in hypertensive patients with significant proteinuria. Proteinuria was evaluated by 24-h home urine collection for all patients. A total of 35 proteinuric (>0.1 gday) patients with uncontrolled BP (>13585 mmHg) were randomized to receive either cilnidipine (n 18) or amlodipine (n 17) after a 6-month treatment with RAS inhibitors and were followed for 48 weeks. At baseline, the cilnidipine group was older and had lower body mass index (BMI) compared to the amlodipine group. After 32 weeks of treatment, diastolic blood pressure (DBP) was slightly, but significantly reduced, in the cilnidipine group, although systolic blood pressure (SBP) and mean BP did not differ. The urinary protein did not differ at baseline (cilnidipine group 0.48 gday, amlodipine group 0.52 gday); however, it significantly decreased in the cilnidipine group (0.22 gday) compared to the amlodipine group (0.50 gday) after 48 weeks of treatment. Our findings suggest that cilnidipine is superior to amlodipine in preventing the progression of proteinuria in hypertensive patients even undergoing treatment with RAS inhibitors.

Original languageEnglish
Pages (from-to)400-405
Number of pages6
JournalClinical and Experimental Hypertension
Volume32
Issue number6
DOIs
Publication statusPublished - Oct 1 2010

Fingerprint

Urine Specimen Collection
Renin-Angiotensin System
Amlodipine
Proteinuria
Blood Pressure
N-Type Calcium Channels
Therapeutics
L-Type Calcium Channels
cilnidipine
Calcium Channel Blockers
Arterioles
Body Mass Index
Morbidity
Kidney
Mortality

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology

Cite this

Antiproteinuric effect of cilnidipine in hypertensive japanese treated with renin-angiotensin-system inhibitors-A multicenter, open, randomized trial using 24-hour urine collection. / Miwa, Yoshikazu; Tsuchihashi, Takuya; Ohta, Yuko; Tominaga, Mitsuhiro; Kawano, Yuhei; Sasaguri, Toshiyuki; Ueno, Michio; Matsuoka, Hiroaki.

In: Clinical and Experimental Hypertension, Vol. 32, No. 6, 01.10.2010, p. 400-405.

Research output: Contribution to journalArticle

Miwa, Yoshikazu ; Tsuchihashi, Takuya ; Ohta, Yuko ; Tominaga, Mitsuhiro ; Kawano, Yuhei ; Sasaguri, Toshiyuki ; Ueno, Michio ; Matsuoka, Hiroaki. / Antiproteinuric effect of cilnidipine in hypertensive japanese treated with renin-angiotensin-system inhibitors-A multicenter, open, randomized trial using 24-hour urine collection. In: Clinical and Experimental Hypertension. 2010 ; Vol. 32, No. 6. pp. 400-405.
@article{1b88d82bc1044113859a4f1eb2232293,
title = "Antiproteinuric effect of cilnidipine in hypertensive japanese treated with renin-angiotensin-system inhibitors-A multicenter, open, randomized trial using 24-hour urine collection",
abstract = "Sustained proteinuria is an important risk factor for not only renal but also cardiovascular morbidity and mortality. Although inhibitors of the renin-angiotensin system (RAS) have been shown to reduce proteinuria. Monotherapy with those drugs is often insufficient for optimal blood pressure (BP)-lowering and therefore, combined therapy is needed. Recent reports suggested that cilnidipine, a dual L-N-type calcium channel blocker, has renoprotective effect by dilating both efferent and afferent arterioles. In this study, a multicenter, open, randomized trial was designed to compare the antiproteinuric effect between cilnidipine and amlodipine when coupled with RAS inhibitors in hypertensive patients with significant proteinuria. Proteinuria was evaluated by 24-h home urine collection for all patients. A total of 35 proteinuric (>0.1 gday) patients with uncontrolled BP (>13585 mmHg) were randomized to receive either cilnidipine (n 18) or amlodipine (n 17) after a 6-month treatment with RAS inhibitors and were followed for 48 weeks. At baseline, the cilnidipine group was older and had lower body mass index (BMI) compared to the amlodipine group. After 32 weeks of treatment, diastolic blood pressure (DBP) was slightly, but significantly reduced, in the cilnidipine group, although systolic blood pressure (SBP) and mean BP did not differ. The urinary protein did not differ at baseline (cilnidipine group 0.48 gday, amlodipine group 0.52 gday); however, it significantly decreased in the cilnidipine group (0.22 gday) compared to the amlodipine group (0.50 gday) after 48 weeks of treatment. Our findings suggest that cilnidipine is superior to amlodipine in preventing the progression of proteinuria in hypertensive patients even undergoing treatment with RAS inhibitors.",
author = "Yoshikazu Miwa and Takuya Tsuchihashi and Yuko Ohta and Mitsuhiro Tominaga and Yuhei Kawano and Toshiyuki Sasaguri and Michio Ueno and Hiroaki Matsuoka",
year = "2010",
month = "10",
day = "1",
doi = "10.3109/10641961003667914",
language = "English",
volume = "32",
pages = "400--405",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Antiproteinuric effect of cilnidipine in hypertensive japanese treated with renin-angiotensin-system inhibitors-A multicenter, open, randomized trial using 24-hour urine collection

AU - Miwa, Yoshikazu

AU - Tsuchihashi, Takuya

AU - Ohta, Yuko

AU - Tominaga, Mitsuhiro

AU - Kawano, Yuhei

AU - Sasaguri, Toshiyuki

AU - Ueno, Michio

AU - Matsuoka, Hiroaki

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Sustained proteinuria is an important risk factor for not only renal but also cardiovascular morbidity and mortality. Although inhibitors of the renin-angiotensin system (RAS) have been shown to reduce proteinuria. Monotherapy with those drugs is often insufficient for optimal blood pressure (BP)-lowering and therefore, combined therapy is needed. Recent reports suggested that cilnidipine, a dual L-N-type calcium channel blocker, has renoprotective effect by dilating both efferent and afferent arterioles. In this study, a multicenter, open, randomized trial was designed to compare the antiproteinuric effect between cilnidipine and amlodipine when coupled with RAS inhibitors in hypertensive patients with significant proteinuria. Proteinuria was evaluated by 24-h home urine collection for all patients. A total of 35 proteinuric (>0.1 gday) patients with uncontrolled BP (>13585 mmHg) were randomized to receive either cilnidipine (n 18) or amlodipine (n 17) after a 6-month treatment with RAS inhibitors and were followed for 48 weeks. At baseline, the cilnidipine group was older and had lower body mass index (BMI) compared to the amlodipine group. After 32 weeks of treatment, diastolic blood pressure (DBP) was slightly, but significantly reduced, in the cilnidipine group, although systolic blood pressure (SBP) and mean BP did not differ. The urinary protein did not differ at baseline (cilnidipine group 0.48 gday, amlodipine group 0.52 gday); however, it significantly decreased in the cilnidipine group (0.22 gday) compared to the amlodipine group (0.50 gday) after 48 weeks of treatment. Our findings suggest that cilnidipine is superior to amlodipine in preventing the progression of proteinuria in hypertensive patients even undergoing treatment with RAS inhibitors.

AB - Sustained proteinuria is an important risk factor for not only renal but also cardiovascular morbidity and mortality. Although inhibitors of the renin-angiotensin system (RAS) have been shown to reduce proteinuria. Monotherapy with those drugs is often insufficient for optimal blood pressure (BP)-lowering and therefore, combined therapy is needed. Recent reports suggested that cilnidipine, a dual L-N-type calcium channel blocker, has renoprotective effect by dilating both efferent and afferent arterioles. In this study, a multicenter, open, randomized trial was designed to compare the antiproteinuric effect between cilnidipine and amlodipine when coupled with RAS inhibitors in hypertensive patients with significant proteinuria. Proteinuria was evaluated by 24-h home urine collection for all patients. A total of 35 proteinuric (>0.1 gday) patients with uncontrolled BP (>13585 mmHg) were randomized to receive either cilnidipine (n 18) or amlodipine (n 17) after a 6-month treatment with RAS inhibitors and were followed for 48 weeks. At baseline, the cilnidipine group was older and had lower body mass index (BMI) compared to the amlodipine group. After 32 weeks of treatment, diastolic blood pressure (DBP) was slightly, but significantly reduced, in the cilnidipine group, although systolic blood pressure (SBP) and mean BP did not differ. The urinary protein did not differ at baseline (cilnidipine group 0.48 gday, amlodipine group 0.52 gday); however, it significantly decreased in the cilnidipine group (0.22 gday) compared to the amlodipine group (0.50 gday) after 48 weeks of treatment. Our findings suggest that cilnidipine is superior to amlodipine in preventing the progression of proteinuria in hypertensive patients even undergoing treatment with RAS inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=78049423503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049423503&partnerID=8YFLogxK

U2 - 10.3109/10641961003667914

DO - 10.3109/10641961003667914

M3 - Article

C2 - 20828221

AN - SCOPUS:78049423503

VL - 32

SP - 400

EP - 405

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 6

ER -